Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spironolactone improves left atrial function and atrioventricular coupling in patients with resistant hypertension.

The international journal of cardiovascular imaging·2023
Same author

Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2023
Same author

Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension.

Hypertension (Dallas, Tex. : 1979)·2022
Same author

Diastolic function: modeling left ventricular untwisting as a damped harmonic oscillator.

Physiological measurement·2022
Same author

Elucidation of obstructive sleep apnoea related blood pressure surge using a novel continuous beat-to-beat blood pressure monitoring system.

Journal of hypertension·2021
Same author

Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change.

Journal of the American Heart Association·2021

Related Experiment Video

Updated: Jun 4, 2026

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

Aldosteronism and resistant hypertension.

Maria Czarina Acelajado1, David A Calhoun

  • 1Vascular Biology and Hypertension Program, University of Alabama at Birmingham, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294-2041, USA.

International Journal of Hypertension
|February 19, 2011
PubMed
Summary

Resistant hypertension (RHTN) is often linked to primary aldosteronism (PA). Treating with MR antagonists significantly lowers blood pressure in RHTN patients, suggesting aldosterone

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Related Experiment Videos

Last Updated: Jun 4, 2026

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Area of Science:

  • Endocrinology and Hypertension Research
  • Cardiovascular Disease Epidemiology

Background:

  • Resistant hypertension (RHTN) affects patients with uncontrolled blood pressure despite optimal medication regimens.
  • Primary aldosteronism (PA) is prevalent in RHTN (14-23%) and associated with increased cardiovascular risk (stroke, myocardial infarction, arrhythmias).
  • Obstructive sleep apnea (OSA) is also strongly linked to RHTN, with potential causal interrelations yet to be fully understood.

Purpose of the Study:

  • To investigate the role of aldosterone in resistant hypertension and its cardiovascular implications.
  • To explore the therapeutic effect of mineralocorticoid receptor (MR) antagonists in RHTN patients.

Main Methods:

  • Analysis of prospective studies on the incidence of PA in RHTN.
  • Review of cardiovascular outcomes in patients with PA versus those without.
  • Evaluation of the impact of MR antagonist therapy on blood pressure in RHTN.

Main Results:

  • PA is significantly more common in RHTN patients compared to the general hypertensive population.
  • RHTN is associated with adverse cardiovascular outcomes, with PA potentially contributing to this risk.
  • MR antagonists demonstrate a substantial blood pressure-lowering effect in RHTN patients, irrespective of biochemical PA evidence.

Conclusions:

  • Aldosterone plays a critical role in driving treatment resistance in RHTN.
  • MR antagonists are effective in managing RHTN, indicating the importance of targeting aldosterone pathways.
  • Further research is needed to elucidate the interplay between PA, OSA, and RHTN.